Aryl isoguanines
AssigneeEuro-Celtique S.A.
InventorsDavid Cavalla, Peter Hofer, Mark Chasin
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds having formula (II): wherein: Q3, Q6a, Q6b and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and R3, R6a, R6b and R8 are independently hydrogen, aryl or heteroraryl, optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that: Q3R3 is not hydrogen or methyl. The compounds are effective PDE IV inhibitors and possess improved PDE IV inhibition and improved selectivity with regard to PDE III inhibition.
Claims16
A compound of formula II:
- wherein:
- Q3, Q6a, Q6b, and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and
- R3, R6a, R6b, and R8 are independently hydrogen, aryl, or heteroaryl, which is optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that Q3R3 is not hydrogen or methyl;
- and
- pharmaceutically acceptable salts thereof.
A method of treating a mammal suffering from a disease state selected from the group consisting of asthma, allergies, depression and rhinitis, comprising administering an effective amount of the compound of formula (II):
- wherein:
- Q3, Q6a, Q6b, and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and
- R3, R6a, R6b, and R8 are independently hydrogen, aryl, or heteroaryl, which is optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that Q3R3 is not hydrogen or methyl;
- and
- pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of formula (II):
- wherein:
- Q3, Q6a, Q6b, and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and
- R3, R6a, R6b, and R8 are independently hydrogen, aryl, or heteroaryl, which is optionally substituted by halogen, hydroxy, alkoxy, nitro, cyano and carboxy, provided that Q3R3 is not hydrogen or methyl;
- and
- pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.